What is the market price of a box of Apelvis-Piqray in India?
Alpelisib (Alpelisib)-Piqray is a targeted PI3Kα inhibitor originally developed by the Swiss company Novartis for the treatment of specific types of PIK3CA mutated breast cancer. Although the drug is sold at a higher price in European and American markets, the Indian market provides a more competitively priced version due to its imitation policy and production cost advantages. The original drug is usually produced by the Indian branch of Novartis Pharmaceuticals, which ensures that the quality of the drug is consistent with that of foreign countries, while significantly reducing the burden of treatment.
In the Indian drug market, the price of Apelvis-Piqray is relatively affordable. Taking the 150mg specification and 28 tablets per box as an example, the price quoted in the Indian market is generally between 5,000 and 6,000 yuan. The specific selling price will vary depending on exchange rate fluctuations, availability in local pharmacies, and transportation methods. If patients obtain it through formal purchasing channels, they may need to pay additional international shipping and service fees. The overall cost will increase slightly, but it is still far lower than the retail price in Europe and the United States.
It is worth noting that Apelvis sold in India is usually still the official original drug of Novartis, not a generic version, which is different from other generic drugs. However, if patients consider purchasing drugs from India, they must carefully choose a drug supplier with legal qualifications to avoid problems with counterfeit drugs or improper transportation caused by irregular channels.
It needs to be emphasized that regardless of whether you choose to purchase drugs in India, as a type of targeted anti-tumor drug, the use of Apelvis should be based on clear genetic testing results and a treatment plan should be formulated under the guidance of professional oncologists. Especially when endocrine drugs such as fulvestrant are used in combination, the overall treatment strategy and possible adverse reactions, such as hyperglycemia, rash or gastrointestinal discomfort, need to be considered. In addition, indicators such as blood sugar, liver and kidney function should also be monitored regularly to ensure the safety of medication.
Reference materials:https://www.piqray.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)